Target Trial Emulation of Empiric Antibiotics on Clinical Outcomes in Moderately Immunocompromised Patients Hospitalized With Pneumonia
Clinical Infectious Diseases · 2026
DOI: 10.1093/cid/ciaf344 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2026. Verfasst von Louis Saravolatz und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Internal Medicine, Michigan Medicine, Ann Arbor, Michigan, USA. Hauptthemen laut MEDLINE: Immunocompromised Host, Anti-Bacterial Agents, Community-Acquired Infections, Pneumonia. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Blue Cross Blue Shield of Michigan, Blue Care Network, BCBSM.
Abstract (Originalsprache)
Background
Immunocompromised patients are often excluded from pneumonia trials, guidelines, and stewardship interventions. The objective of this study was to evaluate whether empiric broad-spectrum antibiotic (BSA) treatment impacts mortality and other clinical outcomes in moderately immunocompromised patients without risk factors for multidrug-resistant organisms (MDROs) hospitalized with community-acquired pneumonia.
Methods
This was a target trial emulation including moderately immunocompromised (asplenia, hematologic malignancies, solid organ malignancy receiving chemotherapy, kidney transplant >1 year prior, congenital/acquired immunodeficiency, and receiving immunosuppressive medications) patients with pneumonia without risk factors for MDROs at 69 hospitals in the Michigan Hospital Medicine Safety Consortium. This study compared the receipt of empiric BSAs against antibiotics targeting typical respiratory pathogens on hospital day 1 or 2. The primary outcome was mortality. Secondary outcomes included length of stay, transfer to the intensive care unit (ICU) and 30-day readmission, emergency department visit, Clostridioides difficile infection, and antibiotic-associated adverse events.
Results
Of 2706 moderately immunocompromised patients with pneumonia, 59% (n = 1596) received empiric BSAs. Methicillin-resistant Staphylococcus aureus and resistant gram-negative bacteria were rare (94/2706 [3.5%]). After adjustment, empiric BSA treatment was not associated with mortality, but was associated with readmission (adjusted hazard ratio [aHR], 1.32 [95% confidence interval {CI], 1.05–1.66]), transfer to ICU (aHR, 2.65 [95% CI, 1.32–5.30]), and longer hospitalization (adjusted rate ratio, 1.14 [95% CI, 1.10–1.19]).
Conclusions
Immunocompromised patients hospitalized with pneumonia often receive empiric BSAs despite low rates of MDROs. Empiric BSA use was not associated with mortality, but was associated with harm, including 30-day readmission, transfer to ICU, and longer duration of hospitalization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Infectious Diseases, Department of Internal Medicine, Michigan Medicine, Ann Arbor, Michigan, USA.
- Division of General Internal Medicine, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA.
- Division of Health System Innovation and Research, Department of Population Health Science, University of Utah School of Medicine, Salt Lake City, Utah, USA.
- Division of Hospital Medicine, Department of Internal Medicine, Michigan Medicine, Ann Arbor, Michigan, USA.
- Center for Clinical Management Research, Veterans Affairs Ann Arbor Health System, Ann Arbor, Michigan, USA.
- Medicine Service, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan, USA.
ORCID-Profile: Louis Saravolatz, Valerie M Vaughn, Jennifer K Horowitz, David Paje, Danielle Osterholzer
Förderung
- Blue Cross Blue Shield of Michigan
- Blue Care Network
- BCBSM
Zitieren
APA
Saravolatz, L., Gandhi, T. N., Vaughn, V. M., Ratz, D., Horowitz, J. K., Gupta, A., McLaughlin, E., Czilok, T., Weinmann, A., Paje, D., Malani, A. N., Burdick, S., Osterholzer, D., Flanders, S. A., & Petty, L. A. (2026). Target Trial Emulation of Empiric Antibiotics on Clinical Outcomes in Moderately Immunocompromised Patients Hospitalized With Pneumonia. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaf344
Vancouver
Saravolatz L, Gandhi TN, Vaughn VM, Ratz D, Horowitz JK, Gupta A, et al. Target Trial Emulation of Empiric Antibiotics on Clinical Outcomes in Moderately Immunocompromised Patients Hospitalized With Pneumonia. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciaf344
BibTeX
@article{Saravolatz2026,
author = {Saravolatz, Louis and Gandhi, Tejal N and Vaughn, Valerie M and Ratz, David and Horowitz, Jennifer K and Gupta, Ashwin and McLaughlin, Elizabeth and Czilok, Tawny and Weinmann, Allison and Paje, David and Malani, Anurag N and Burdick, Stephanie and Osterholzer, Danielle and Flanders, Scott A and Petty, Lindsay A},
title = {Target Trial Emulation of Empiric Antibiotics on Clinical Outcomes in Moderately Immunocompromised Patients Hospitalized With Pneumonia},
journal = {Clinical Infectious Diseases},
year = {2026},
doi = {10.1093/cid/ciaf344}
}
EUVIMED